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Abstract  
Objectives: In recent years, numerous frameworks have been developed to enhance the legitimacy of 
health technology assessment processes. Despite efforts to implement these “legitimacy frameworks”, 
medicines funding decisions can still be perceived as lacking in legitimacy. We therefore sought to 
examine stakeholder views on factors that they think should be considered when making decisions 
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about the funding of high-cost breast cancer therapies, focusing on those that are not included in 
current frameworks and processes. 
Methods: We analyzed published discourse on the funding of high-cost breast-cancer therapies. 
Relevant materials were identified by searching the databases Google, Google Scholar and Factiva in 
August 2014 and July 2016 and these were analyzed thematically. 
Results: We analyzed 50 published materials and found that stakeholders, for the most part, want to be 
able to access medicines more quickly and at the same time as other patients and for decision-makers to 
be more flexible with regards to evidence requirements and to use a wider range of criteria when 
evaluating therapies. Many also advocated for existing process to be accelerated or bypassed in order to 
improve access to therapies.  
Conclusions: Our results illustrate that a stakeholder-derived conceptualization of legitimacy emphasizes 
principles of accelerated access, and is not fully accounted for by existing frameworks and processes 
aimed at promoting legitimacy. However, further research examining the ethical, political and clinical 
implications of the stakeholder claims raised here is needed before firm policy recommendations can be 
made.   
Keywords  
pharmaceutical funding decisions; resource allocation; stakeholder engagement; breast cancer; 
accelerated access 
 
Introduction 
Healthcare resource allocation inevitably involves adjudication between several relevant values 
(including clinical- and cost-effectiveness, solidarity, compassion and autonomy) (1). However, in a 
liberal democratic society, it is almost impossible to gain agreement on which principles should be 
privileged (2). Individuals in these societies hold diverse moral views, all of which may be equally valid 
(this is termed value or moral pluralism (3)); conflicts between these inevitably lead to disagreements 
about the best way to distribute scarce healthcare resources.  
Despite this, resource allocation decisions must be made. Thus, many ethicists and political scientists 
have concluded that the goal should not be for all stakeholders to agree about the best course of action, 
but rather, for procedures to be put in place that stakeholders can understand and accept as 
“legitimate”. There are many definitions of legitimacy and a vast literature on the legitimacy of political 
decisions. For the purposes of this paper we have chosen to adopt the definition espoused by Daniels 
and Sabin (2): “legitimacy” refers to a situation where the decision to grant authority to individuals or 
institutions to set limits to health care is seen to be in accordance with established rules, principles or 
standards.  
Perceived legitimacy is important, both because it is an essential feature of liberal democracy (4) and 
because, without it, attempts will inevitably be made to circumvent decision-making processes (i.e. its 
justification is both moral and pragmatic). While there is not necessarily anything wrong with efforts to 
circumvent processes that are perceived to be ineffective or immoral, such efforts can create problems 
if they are established without due consideration for costs and opportunity costs (regardless of whether 
they increase access). An example of this is the UK Cancer Drugs Fund, which was established in 2010 to 
provide subsidized access to cancer medicines that did not meet National Institute for Health and Care 
Excellence’s (NICE) standards of cost-effectiveness (5). The fund was established partly in response to 
concerns that NICE decisions were not in accordance with the principle that “society values health 
benefits to patients with cancer more highly… than benefits to patients suffering other conditions” (6). 
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However, after greater-than-expected demand (leading the fund to exceed its budget by 50% in 2014), it 
was deemed to be unsustainable and was recently converted to a managed access scheme that will 
provide funding for therapies for up to two years while further efficacy and cost-effectiveness data are 
gathered (7). While it is important that funding systems are flexible and responsive to societal priorities, 
the establishment of unsustainable “alternative” systems and ad hoc funding in response to public 
pressure does little to promote either efficiency or equity and demonstrates the importance of 
maximizing the legitimacy of existing systems.  
A range of frameworks, procedures and guiding principles (2, 8, 9) (henceforth “legitimacy frameworks”) 
have been devised to guide those making resource allocation decisions (figure 1). Additionally, much 
recent academic and political work has focused on methods for eliciting the values of patients and the 
general public and incorporating these into decision-making. These efforts have generally fallen into two 
groups: those that aim to determine the best way to involve patients and the general public in health 
policy decisions (and the health technology assessment that informs them) (including Degeling (10) and 
Wortley (11)) and those that aim to determine their values and preferences regarding legitimate 
resource allocation decisions, primarily through quantitative methods such as surveys and discrete 
choice experiments (including Linley (6) and Green (12)). Two well-recognized examples of organizations 
that have developed methods to incorporate the values of patients and the general public are the UK’s 
NICE “Patient and Public Involvement Programme” (13) and a system for patient group involvement in 
the Canadian Agency for Drugs and Technologies in Health’s (CADTH) Common Drug Review (CDR) (14). 
Efforts to ensure the legitimacy of medicines funding decisions have had some success. While some 
degree of controversy is to be expected (and desired), most decisions are accepted by stakeholders. 
However, there is some evidence that medicines funding processes may not be as legitimate as they 
need to be. It is not unusual to see media articles decrying the difficulties that patients have in accessing 
what they view as potentially life-saving therapies that are not currently subsidized and describing the 
measures that they will go to in order to obtain access.  There are also ongoing examples of politicians 
promising to fund medicines after they have been deemed not to be cost-effective by health technology 
assessment bodies. Finally, a number of recent government reviews (including the 2015 Australian 
Senate Inquiry into the Availability of New, Innovative and Specialist Cancer Drugs (15) and the UK 
government’s Accelerated Access Review (16)) have been established in response to concerns about the 
adequacy of current reimbursement systems. 
There is also a significant body of work examining the legitimacy of healthcare resource allocation 
processes, which has found that existing processes have several serious limitations. For example, 
transparency of decision-making, consideration of relevant perspectives (particularly those of patients 
and the general public) and use of explicit and consistent decision-making processes have all been found 
to be important to legitimacy but are not always evident in existing processes (17, 18). In recognition of 
these shortcomings, there is now an ongoing international research program (1) that draws on ethics, 
philosophy, health economics, political science and health technology assessment to identify social 
value challenges faced in specific priority-setting contexts and to facilitate their cross-national 
comparative study. In most cases, resource allocation processes are compared to existing legitimacy 
frameworks and found to be lacking in certain, pre-defined ways. However, it is possible that current 
frameworks are themselves limited by pre-conceptions as to what “rules, principles or standards” 
should be applied. In order to explore this, we conducted a qualitative analysis of published stakeholder 
perspectives regarding the legitimacy of decision-making processes for the funding of high-cost breast 
cancer medicines. Our research question was:  What if any factors, other than those espoused in 
existing legitimacy frameworks, do stakeholders think should be considered when making decisions 
about the funding of high-cost breast cancer therapies?  
Methods  
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Choice of high-cost breast cancer medicines as a case study  
The medicines chosen for this case study were the high-cost breast cancer medicines referred to as HER2 
inhibitors. Although the phrase “high-cost medicine” is used frequently, there is no agreed-upon cut-off; 
here, we consider any medicine whose price was considered to have a major influence on the ability of 
funders to subsidise it to be a “high-cost medicine”. Trastuzumab (marketed as Herceptin and approved 
for use in metastatic breast cancer by the US Food and Drug Administration (FDA) in 1998 and early 
stage breast cancer in 2006 (19)) was the first agent in this class; trastuzumab emtasine (Kadcyla) and 
pertuzumab (Perjeta) were both approved by the FDA in 2013 (20, 21). We chose these medicines for 
our case study for several reasons. First, breast cancer is an active area of pharmaceutical research, with 
a number of breast cancer therapies either in development or recently entering the market. Decisions 
about the funding of HER2 inhibitors have also caused considerable controversy around the world. 
Following decisions in several countries not to fund these therapies, media articles highlighted 
“desperate” women pleading for access and derided governments as callous, out of touch with 
community values or incompetent for withholding this; many jurisdictions established ad hoc funding 
processes to provide access to these therapies (22, 23). Overall, there appears to be a perception that 
decisions about the funding of these therapies have not been in accordance with accepted standards of 
fairness and compassion, suggesting significant problems with their perceived legitimacy. While there 
has been some academic exploration of funding decisions for these therapies and the discourses 
surrounding these (including MacKenzie (22), Gabe (23) and Fenton (24)), most of this has aimed to 
describe how these decisions were made and has not explicitly addressed their perceived legitimacy (or 
otherwise) from multiple stakeholder perspectives. 
Identification of Published Material  
The databases Google, Google Scholar and Factiva were searched in August 2014 and July 2016 using 
the following terms: (breast cancer drugs OR cancer drugs OR breast cancer medicines OR cancer 
medicines OR breast cancer medications OR cancer medications OR Herceptin OR trastuzumab OR 
pertuzumab OR Perjeta OR Kadcyla) AND (access OR fund* OR subsid*). Our aim was to recall as many 
articles as possible and to then select articles that represented a variety of stakeholder groups, locations 
and types of decision-making processes. We therefore used general databases and kept our search 
terms broad.  
We subsequently included material in which stakeholders discussed their views on or experiences with, 
gaining access to high-cost breast cancer therapies that were published in English between 2005 and 
2016. The process for selecting material was as follows: the most recent material was analyzed first; 
characteristics such as stakeholder group, geographical location and type of decision-making process 
were identified; and if we already had similar material from that group, location or process then we 
moved onto the next piece. As a result, our final set of articles included both very recent articles and 
some older articles where it was necessary to continue searching for articles representing particular 
groups, locations and/or decision-making processes. We emphasize that our goal was to gain an 
overview of stakeholder perspectives across jurisdictions and not to draw out fine distinctions between 
sub-groups unless patterns were obvious.  
Data Analysis  
An inductive approach was taken to data analysis. This involved: initial coding of paragraphs where 
opinions were expressed using “gerunding” (encoding action or process); synthesis of codes into 
categories; focused coding using these categories; and abstraction into concepts (25). A process of 
constant comparison was used, with continual refinement and enrichment of codes. Data analysis 
continued until categories were saturated (i.e. all codes appeared to fit under one or more existing 
categories and all concepts were fully described and well-understood). Categories and concepts were 
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then organized to answer the research question. JP coded all articles and WL coded approximately 10% 
of these; detailed discussion was used to ensure consistency in emergent codes, categories and 
concepts.  
Results  
Material Analyzed  
The search strategy revealed more than 15 million hits and 50 documents were analyzed before 
thematic saturation was reached. Supplementary table S1 shows the hits in each database and how 
many articles were included in the final sample. Material analyzed included media releases (14), opinion 
pieces in popular media (10) and medical literature (10), letters in medical journals (7) and popular 
media (6), submissions to decision-making bodies (3) and reports and position statements (one of each). 
Stakeholders represented include doctors (14), members of the general public (10), patients (7), 
politicians (7), pharmaceutical companies (6) and multiple stakeholder groups (3). Material analyzed 
related to decisions in New Zealand (18), the United Kingdom (15), Australia (11), Canada (3), Europe 
and USA (1 each); one piece did not have an obvious geographical focus.  
The “standard” elements of legitimacy emerged frequently. For example, stakeholders emphasized the 
need for decisions to be evidence-based, for consistency and transparency in decision-making, for all 
parties involved to follow pre-defined processes, for decisions to be made by people with relevant 
expertise and without vested interests and for due consideration of community values. We also 
identified three additional factors that many stakeholders think should be considered when making 
decisions about the funding of high-cost breast cancer therapies: 1) Providing timely access to cancer 
medicines; 2) Greater flexibility with evidentiary requirements and evaluation criteria; and 3) 
Accelerating or bypassing existing processes when making decisions about cancer therapies. 
Supplementary table 2 shows the codes, categories and concepts that we identified. Citations for 
quotes in the following sections are shown in supplementary figure 1.  
 
Providing Timely Access to Cancer Medicines 
Many stakeholders emphasized the importance of timely access to new medicines. They asserted that 
decisions about the funding of cancer medicines were “unique” due to the low life-expectancy of many 
cancer patients and the serious consequences of delayed access to therapies.  
Unlike many chronic conditions, cancer patients do not have the luxury of several years to wait 
for new advances to be made available…. Patients have been dying early because of delayed 
access to treatment. 
Australian multiple stakeholder group Cancer Drugs Alliance discussing the impact of delays in 
access to cancer medicines, 2013 (a). 
Patients and the general public also cited the importance of funding new therapies so that all patients, 
irrespective of where they come from, can access these at the same time. They noted significant 
differences both in the time taken for a positive funding recommendation across jurisdictions and the 
ability of patients within the same healthcare system to access therapies. Inequities were perceived to 
be due to factors such as where the patient lives, the type and stage of their disease, the level of funding 
that their disease receives (e.g. differences in resources allocated to men’s and women’s health) and 
their own personal resources.  
Mrs. Rogers might be saved from a particularly virulent form of breast cancer by a drug called 
Herceptin [trastuzumab]… But it is only licensed for breast cancer treatment in its later stages, 
and Ann Marie is in the early stages. [If] she lived in Isle of Wight, or Yorkshire, or Leicestershire 
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or down the M4 in Somerset she would be given the chance to live. If Ann Marie was rich, the gift 
of life would be hers too. But she can't afford the £26,000 a year the drug costs.  
Member of the general public discussing the funding of Herceptin (trastuzumab) for patients 
with early breast cancer in the UK, 2006 (b). 
However, others (particularly payers) emphasized that any funding decision must be made with due 
regard to local policies and procedures and healthcare environments.  
 
Greater Flexibility with Evidentiary Requirements and Evaluation Criteria  
Many stakeholders (particularly patients and manufacturers) expressed a belief that current evidence 
requirements were too strict and impeded patient access to therapies. Manufacturers noted difficulties 
generating data of an acceptable quality for regulatory and reimbursement decisions due to the 
challenges of recruiting patients for oncology clinical trials and conducting randomized controlled trials 
(RCT) in this setting. They thus advocated for decision-makers to be realistic and prepared to base 
decisions on different types of evidence (including non-randomized, open label and single arm trials).   
However, others (particularly payers and doctors) thought that only treatments of proven efficacy 
should receive funding, and that decision-makers should be cautious about replacing or supplementing 
proven treatments with newer ones of unknown efficacy.  
We could fund Herceptin [trastuzumab] if we did not treat 355 patients receiving adjuvant 
treatment (16 of whom would be cured) or 208 patients receiving palliative chemotherapy, and if 
we found £0.5m from another source. We will be the ones to tell [these untreated patients that] 
they are not getting a treatment that has been proved to be effective, which costs relatively 
little, because it is not the “treatment of the moment”.  
Doctor discussing the opportunity costs involved in funding Herceptin (trastuzumab) for early 
breast cancer in the UK, 2006 (c). 
Additionally, many stakeholders argued that decision-makers should use a wider range of criteria to 
evaluate new therapies. They emphasized that “hard endpoints” such as overall survival were not the 
only meaningful measure of efficacy and wanted decision-makers to be more willing to make use of 
surrogate endpoints (such as progression-free survival or tumor shrinkage) when making 
reimbursement decisions. Patients and manufacturers also stressed the importance of considering 
factors such as quality of life and patient experiences of disease and therapy. Some noted that the major 
advantage of newer therapies was a reduction in side effects compared to traditional cytotoxic agents. 
However, others emphasized the need to give proper consideration to both the risks and benefits of 
treatment and to adequately determine the safety of new therapies- including the apparently less toxic 
“targeted” therapies.  
 
Accelerating or Bypassing Existing Processes When Making Decisions About Cancer Therapies 
Existing processes were seen by some to be inadequate for the evaluation of cancer therapies, due to 
the time taken to achieve reimbursement and difficulty demonstrating cost-effectiveness. There was 
concern about the ability of existing processes to accommodate newer targeted therapies and the 
evolving oncological indications of existing therapies.  
The case has been made that, due to the nature of the current and future generation of cancer 
drugs, which are more targeted, require different technology and smaller patient groups that our 
present requirements for evidence and processes need to be looked at in a new light.  
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Australian multiple stakeholder group Cancer Voices Australia outlining the need for changes 
to the processes used for the evaluation of cancer therapies, 2014 (d).  
Manufacturers and patients in particular advocated for the increased use of accelerated or alternative 
processes to expedite the provision of funding for cancer therapies.  
However, others (particularly doctors and payers) emphasized the importance of letting existing 
processes- established to ensure that medicines are safe, effective and affordable for healthcare 
systems- run their course.  
This raises several important issues…it is pre-empting the evaluations of both the European 
Agency for the Evaluation of Medicinal Products (EMEA, the licensing agency) and the National 
Institute for Health and Clinical Excellence (NICE), the body set up to advise the government on 
value for money in the NHS. 
UK doctor discussing the government’s decision to test all women with early breast cancer for 
HER2 overexpression to determine their eligibility for treatment with Herceptin (trastuzumab) 
before it was approved for this indication or had undergone health technology assessment, 
2005 (e).  
 
Discussion  
To our knowledge, this is the first study to inductively examine the perceived legitimacy of medicines 
funding decisions from multiple stakeholder perspectives and across several jurisdictions and decision-
making systems. We have demonstrated that stakeholders- particularly patients and manufacturers- 
want access to cancer medicines in a way that is procedurally efficient and epistemologically flexible, 
even if this means bypassing or substantially altering existing HTA and resource allocation processes.  
One possible interpretation of these findings is that processes themselves are perceived to be 
legitimate, but there is ongoing (and predictable) discomfort with specific decisions emerging from 
these. We believe, however, that our findings point to problems with perceived legitimacy because 
decision-makers are seen to be insufficently attuned to the need for rapid access to cancer medicines, 
and decision-making processes are perceived to be inadequate to this task. We would, therefore, argue 
that perceived legitimacy encompasses factors that are not included in existing “legitimacy 
frameworks”, including the need for decision-makers and the processes in which they operate to be 
sufficiently flexible and responsive to the unique and urgent needs of certain patient groups.  
In many ways, these findings are not surprising because the principles and values that stakeholders 
espoused are consistent with a range of contemporary policy initiatives aimed at accelerating both 
regulatory and reimbursement processes. Several jurisdictions (including Europe (26), the US (27) and 
Japan (28)) have introduced expedited regulatory schemes that enable medicines to be approved earlier 
and on the basis of less complete data (including the use of surrogate markers), with a shift to the 
acquisition of evidence in the post-marketing phase. A number of payers (including US Centers for 
Medicare and Medicaid (29), the UK Department of Health (30) and the Australian Government 
Department of Health (31)) have also introduced frameworks that allow for the use of ‘managed entry’ 
or ‘coverage with evidence development’ schemes. These  provide subsidy for therapies at a price 
justified by the evidence available at the time a decision is made, with ongoing coverage and the final 
price paid determined through the collection of further data (either from the maturation and 
accumulation of clinical trials or “real world” evidence) once they enter the market.  
It would no doubt be reassuring for those advocating for various kinds of “accelerated access” to know 
that stakeholder conceptualizations of legitimacy are aligned with such initiatives. We believe, however, 
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that it is important not to take demands for accelerated access at face value. While there is little to 
argue with when it comes to demands for more efficient processes (except perhaps the question of who 
should pay to support this), many stakeholders also advocated for a relaxation of current evidence 
requirements (for example, wanting decision-makers to base their decisions on different types of 
evidence including the use of non-randomized clinical trials and surrogate endpoints). It is 
understandable that patients in desperate situations might be resentful of evidence standards that 
appear to stand in the way of access to potentially life-saving therapies. However, we must remember 
that current requirements aim to ensure that only sufficiently safe and effective therapies are available 
to patients and that any therapies that are funded have proven to be cost-effective and/or affordable 
for healthcare systems. Relaxation of these requirements increases the risk that patients will be exposed 
to harm, and that payers will fund therapies that later prove to be unsafe and/or ineffective, with 
resulting opportunity costs for healthcare systems.  
One well-known example of such an outcome is the angiogenesis inhibitor bevacizumab (marketed as 
Avastin). This was granted accelerated approval by the FDA for HER2-negative breast cancer in 2008; 
however, this was revoked in 2011 when further follow-up showed no survival benefits and several side 
effects (32). A recent study (33) also examined the effectiveness of a number of cancer therapies 
approved by the FDA on the basis of surrogate endpoints and found that the majority of these had 
unknown or no effects on overall survival. The difficulties of withdrawal from the market or 
disinvestment from technologies that later prove to be unsafe, ineffective or less cost-effective than 
initially thought are also well-recognized (34). The recent changes to the UK’s Cancer Drugs Fund 
(described above) and the current review of Australia’s special fund for the reimbursement of 
treatments for rare diseases (the Life Saving Drugs Program) on the basis of sustainability (35) are other 
salient examples of the risks and opportunity costs associated with accelerated access. Further research 
examining the ethical, political and clinical implications of these claims and how they became 
incorporated into the discourse surrounding the legitimacy of medicines funding decisions is therefore 
needed before accelerated access can be deemed to be the “right” approach to funding medicines, no 
matter how legitimate such processes might be in the eyes of stakeholders.  
Strengths, Limitations and Future Research  
Our chosen methods have some limitations. The use of published material to elicit stakeholder views is 
efficient and generates valuable insights into views that people hold strongly enough to express publicly. 
However, there is inevitably a loss of both the nuance that is possible in verbal communication and 
opportunities for the researcher to probe the subject for more detail and to clarify issues if necessary. 
The reliance on publicly available material also raises the possibility of publication bias. Additionally, our 
decision to examine the most recent material first may have led to identification of several articles 
focused on a recent debate, resulting in a false impression that thematic saturation had been achieved. 
As a result, we may have stopped our analysis too early and missed other important perspectives or 
debates.  Supplementing our research with other methods such as interviews would allow for a more 
complete understanding of stakeholder perspectives on legitimacy in general, and accelerated access 
more specifically.  
Our choice of qualitative methodology also has some limitations. First, as with all qualitative research, 
our work provides only one perspective on a complex phenomenon and the generalizability of our 
results to other settings or stakeholders may be limited (25). In this regard, it should be noted that most 
material analyzed concerned centralized decision-making processes in publicly funded healthcare 
systems and the applicability of our results to systems that are less centralized and utilize a mix of both 
public and private providers, or to decisions in settings such as public hospital drug and therapeutics 
committees, is unknown. It could also be argued that our chosen case-study is unique, meaning that our 
findings have limited utility in determining the legitimacy of medicines funding decisions for other types 
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of cancers and other diseases. Future research could concentrate on other settings and diseases and aim 
to determine whether our results are also applicable here. Second, our decision to sample for maximum 
variation so that no major themes were missed meant that we were unable to draw out fine distinctions 
between the various stakeholder groups unless patterns were obvious. However, our results do appear 
to indicate a divide between the views of patients and manufacturers (who want decision-makers and 
their processes to be more flexible and responsive to urgent needs) on one hand and payers and doctors 
(who emphasize the need to adhere to well-defined epistemological standards and have due regard for 
existing decision-making processes) on the other. Future research using both qualitative and 
quantitative methods would enable us to further tease out relevant differences between subgroups. 
Finally, theoretical ethical analysis would also be useful here, as the question that we are ultimately 
trying to address- what is the best way for us, as a society, to distribute limited healthcare resources- is 
an ethical one. We have already identified some potential ethical issues (e.g. the tension between 
individual autonomy and the need to protect both individuals and health systems), and exploration of 
these in combination with theoretical ethical analysis (such as consideration of theories of social justice) 
will need to occur before any firm recommendations for change can be made.  
 
Conclusion  
This research has generated a detailed account of stakeholder conceptualizations of legitimate decision-
making for the funding of high-cost breast cancer medicines. We have identified several factors that are 
not accounted for by existing frameworks or current decision-making practice, particularly the 
perception that processes are only legitimate if they are sufficiently flexible and responsive to the 
unique and urgent needs of certain patient groups. However, we do not think that these stakeholder 
claims should be taken at face value, even if doing so would increase the perceived legitimacy of 
decision-making processes.  
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Figure 1: Existing frameworks to evaluate medicines funding decisions  
 
Accountability for Reasonableness
 
(2) 
Outlines four conditions that need to be met for a decision-making process to be considered 
“fair”:  
 Publicity: public access to, and transparent reasons for, decisions;  
 Relevance: reasons for decisions are such that fair-minded participants can agree that 
they are relevant;  
 Appeals: mechanism(s) exist to challenge or dispute decisions and  
 Enforcement: there exists some form of voluntary or public regulation to ensure that 
the other conditions are met.  
 
Sibald et al.’s Framework for Successful Priority Setting (8) 
Framework consists of ten elements related to both process and outcomes that are needed for 
successful priority setting to occur.  
Process elements:  
 Stakeholder engagement; 
 Use of an explicit process; 
 Good information management, including both the information made available to 
decision-makers and how this was utilized; 
 Consideration of values and context and 
 Existence of an appeals mechanism.  
 
Outcome elements:  
 Improved stakeholder understanding of the priority setting process and/or 
organization;  
 Shifted priorities or reallocation of resources; 
 Improved decision-making quality (measured by factors such as appropriate use of 
evidence, consistency of reasoning and compliance with the prescribed process); 
 Stakeholder acceptance and satisfaction and 
 Positive externalities, including positive media coverage or recognition within the 
health sector.   
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Smith et al.’s Framework for High Performance Priority Setting and Resource Allocation 
(9) 
Checklist containing 19 elements across the domains of structures, processes, attitudes and 
behaviors and outcomes that managers can use to determine high performance in priority 
setting and resource allocation. 
  
Structures:  
 Senior management team has the ability and authority to move financial resources; 
 Established mechanisms for staff involvement;  
 Means to coordinate priority setting across all organizational planning processes; 
 Stability of organizational structure and continuity of personnel and  
 Adequate time and resources are dedicated to priority setting and resource allocation.  
 
Processes: 
 Priority setting and resource allocation is based on economic and ethical principles 
(relating to issues such as well-defined and weighted criteria, mechanisms for 
incorporating best available evidence and a decision-review mechanism);  
 Senior management team ensures effective communication, leading to transparency;  
 Skill development occurs throughout the organization and  
 Adequate follow-through on decisions and organization-wide efforts are overseen by a 
skilled internal project coordinator.   
 
Attitudes and Behaviors: 
 Respectful working relationships within the senior management team;  
 Culture of improvement;  
 Decisions are made with a system-wide and long-term perspective;  
 Efforts are made to ensure that priority setting decisions fit with community and social 
values and  
 Senior management team displays strong leadership for priority setting and resource 
allocation.  
 
Outcomes:  
 Actual reallocation of financial resources;  
 Understanding and endorsement of the process by key external stakeholders;  
 Greater understanding of the organization among participants and  
 Priority setting and resource allocation decisions are justified in light of the 
organization’s key values.  
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Supplementary Material  
 
Table S1: Hits in each database and articles included in final sample  
Database Hits Articles in final sample 
Factiva 79 865 26 
Google  Approximately 14 900 000 7 
Google Scholar  21 900 17 
TOTAL Approximately 15 001 765 50 
 
Table S2: Codes, categories and concepts identified  
Concept Categories Codes 
Providing timely access 
to cancer medicines  
 
Recognising the unique position of 
cancer patients  
 
Patients having a limited life 
expectancy  
 
Funders recognising the 
consequences of delayed access the 
therapies for patients and their 
families  
 
Allowing all patients to access new 
cancer therapies at the same time  
 
Patients being able to access new 
cancer therapies regardless of where 
they live   
 
Patients being able to access new 
cancer therapies regardless of what 
type or stage of disease they have  
 
Patients being able to access new 
cancer treatments regardless of their 
ability to pay  
 
Maintaining an egalitarian healthcare 
system  
 
Making the right decision for a 
particular healthcare system  
 
Adapting the healthcare provided to 
local needs  
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Ensuring that decisions are made 
with due regard to local policies, 
procedures and healthcare 
environments  
 
Greater flexibility with 
evidentiary 
requirements and 
evaluation criteria  
 
Recognising the impact of current 
evidence requirements on patient 
access to therapies  
 
Evidence requirements impeding 
access to new cancer therapies  
 
Recognising the difficulties in 
conducting randomised controlled 
trials in oncology  
 
Decision-makers being realistic in 
regards to evidence requirements 
  
Recognising that there may be a 
number of meaningful measures of 
efficacy  
 
Decision-makers being willing to base 
decisions on surrogate endpoints  
 
Considering quality of life  
 
Considering the patient perspective 
of disease and treatment effects that 
are important to patients  
 
Prioritising treatments with proven 
efficacy  
 
Only funding treatments with proven 
efficacy as demonstrated in 
randomised controlled trials  
 
Being cautious about replacing 
proven treatments with newer 
treatments of uncertain efficacy  
 
Giving proper consideration to the 
risks and benefits of treatment  
 
Balancing the risks and benefits of 
treatment when making decisions  
 
Recognising the risks of severe 
toxicities with newer therapies  
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Accelerating or 
bypassing existing 
processes when 
making decisions about 
cancer therapies  
 
Existing processes are inappropriate 
for the evaluation of cancer 
therapies  
 
Recognising the time taken to 
achieve reimbursement for new 
cancer therapies using existing 
processes  
 
Recognising the difficulty of 
demonstrating cost-effectiveness of 
and therefor achieving funding for 
new cancer therapies  
 
Recognising the difficulties of 
accomodating new cancer therapies 
and new indications for existing 
cancer therapies using existing 
processes  
  
Using separate processes to expedite 
funding for cancer therapies  
 
Taking note of the use of specialised 
processes for cancer therapies in 
other jurisdictions and the impact 
this has had on access to therapies 
 
Examining options such as 
specialised funds for new or 
innovative treatments  
 
Using accelerated processes to 
improve access to cancer medicines  
 
Letting existing processes run their 
course  
 
Recognising the importance of 
complying with existing processes  
 
Ensuring that medicines are safe, 
effective and affordable before 
subsidy is provided  
 
Basing decisions on 
evidence  
 
 Basing decisions on the best 
available scientific evidence  
 
Decision-makers considering all 
available data  
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Recognising the strenths and 
limitations of different types of data 
 
Treating cost and price 
appropriately in 
decision-making  
Decision-makers not basing decisions 
on cost alone  
 
Decision-makers not “putting a price 
on life”  
 
Only using cost as a basis for denying 
funding when treatments have 
comparable efficacy  
 
Being realistic about resource 
limitations  
Considering opportunity costs 
 
Ensuring that agencies remain in 
budget  
 
Accepting that not all treatments can 
be funded  
 
Achieving the greatest gains possible 
with limited resources  
 
Paying appropriate prices for new 
cancer therapies  
 
Encouraging and rewarding drug 
development  
 
Ensuring the viability of medicines 
supply  
 
Not paying inflated prices for new 
therapies  
 
Ensuring that treatments are 
affordable for both individual 
patients and the healthcare system 
as a whole  
 
Following proper 
processes when 
Decisions are made by people with 
relevant expertise  
Having the necessary expertise to 
make decisions  
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making decisions  
  
Not allowing politicians, judges or 
doctors to make decisions about the 
subsidy of medicines without expert 
advice  
  
Decision-makers are free of vested 
interests  
 
Decision-makers remaining 
independent and free of external 
influences  
 
Decision-makers providing 
independent advice  
 
Resisting attempts by patients, 
manufacturers and doctors to 
campaign for access to new 
therapies  
 
Campaigning by patients and 
manufacturers as a legitimate action 
to gain access  
 
Ensuring due consideration of  
community values in decision-making  
 
Establishing community values in 
order to inform decision-making  
 
Publicly debating contentious issues 
 
Being transparent in decision-making  
 
Informing all stakeholders of 
decisions in a timely manner  
 
Decision-makers giving clear reasons 
for decisions  
 
Decision-makers being truthful about 
funding options  
 
Decision-makers being able to 
effectively communicate the reasons 
for their decisions to the public   
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Decision-makers being consistent in 
decision-making  
 
Consistently applying criteria to 
different medications and diseases  
 
Ensuring consistency between 
spending in health and other sectors  
 
Ensuring decisions are consistent 
with international best practice  
 
Ensuring consistency between 
decisions in different jurisdictions  
 
 All parties involved in decision-
making following  pre-defined 
processes  
 
Ministers implementing the 
recommendations of advisory bodies  
 
Ministers not delaying funding for 
therapies that have been approved  
 
Manufacturers abiding by industry 
codes of conduct  
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